3 Medical Stocks Standing Out After Crushing Q2 Earnings ExpectationsZacks Investment Research • 08/06/26
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product SalesZacks Investment Research • 08/05/26
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 08/04/26
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth ConferenceBusiness Wire • 07/30/26
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/28/26
Wall Street Analysts Believe Acadia (ACAD) Could Rally 30.89%: Here's is How to TradeZacks Investment Research • 07/23/26
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease CandidateZacks Investment Research • 07/21/26
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease PsychosisBusiness Wire • 07/20/26
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026Business Wire • 07/15/26
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?The Motley Fool • 07/11/26
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett SyndromeZacks Investment Research • 06/29/26
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In FocusSeeking Alpha • 06/29/26
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?Zacks Investment Research • 06/29/26
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome TherapyBenzinga • 06/26/26
The Surprising Reversal That Drove Acadia Pharma Closer To A BreakoutInvestors Business Daily • 06/26/26